B-intervention	0	7	Massage
I-intervention	8	15	therapy
O	16	25	decreases
B-condition	26	32	cancer
I-condition	32	33	-
I-condition	33	40	related
I-condition	41	48	fatigue
O	48	49	:
O	50	57	Results
O	58	62	from
O	63	64	a
O	65	75	randomized
O	76	81	early
O	82	87	phase
O	88	93	trial
O	93	94	.

O	95	101	Cancer
O	101	102	-
O	102	109	related
O	110	117	fatigue
O	118	119	(
O	119	122	CRF
O	122	123	)
O	124	126	is
O	127	128	a
O	129	138	prevalent
O	139	142	and
O	143	155	debilitating
O	156	163	symptom
O	164	175	experienced
O	176	178	by
O	179	185	cancer
O	186	195	survivors
O	195	196	,
O	197	200	yet
O	201	210	treatment
O	211	218	options
O	219	222	for
O	223	226	CRF
O	227	230	are
O	231	238	limited
O	238	239	.

O	240	242	In
O	243	247	this
O	248	253	study
O	253	254	,
O	255	257	we
O	258	267	evaluated
O	268	271	the
O	272	280	efficacy
O	281	283	of
O	284	290	weekly
O	291	298	Swedish
O	299	306	massage
O	307	314	therapy
O	315	316	(
O	316	319	SMT
O	319	320	)
O	321	327	versus
O	328	330	an
O	331	337	active
O	338	345	control
O	346	355	condition
O	356	357	(
O	357	362	light
O	363	368	touch
O	369	370	[
O	370	372	LT
O	372	373	]
O	373	374	)
O	375	378	and
B-control	379	387	waitlist
I-control	388	395	control
I-control	396	397	(
I-control	397	400	WLC
I-control	400	401	)
O	402	404	on
O	405	415	persistent
O	416	419	CRF
O	420	422	in
O	423	429	breast
O	430	436	cancer
O	437	446	survivors
O	446	447	.

O	448	452	This
O	453	458	early
O	459	464	phase
O	464	465	,
O	466	476	randomized
O	476	477	,
O	478	484	single
O	484	485	-
O	485	491	masked
O	491	492	,
O	493	494	6
O	494	495	-
O	495	499	week
O	500	513	investigation
O	514	516	of
O	517	520	SMT
O	520	521	,
O	522	524	LT
O	524	525	,
O	526	529	and
O	530	533	WLC
O	534	542	enrolled
B-total-participants	543	545	66
B-eligibility	546	552	female
I-eligibility	553	558	stage
I-eligibility	559	560	0
I-eligibility	560	561	-
I-eligibility	561	564	III
I-eligibility	565	571	breast
I-eligibility	572	578	cancer
I-eligibility	579	588	survivors
O	589	590	(
O	590	593	age
O	594	599	range
O	599	600	,
B-age	601	603	32
I-age	603	604	-
I-age	604	606	72
I-age	607	612	years
O	612	613	)
B-eligibility	614	617	who
I-eligibility	618	621	had
I-eligibility	622	630	received
I-eligibility	631	638	surgery
I-eligibility	639	643	plus
I-eligibility	644	653	radiation
I-eligibility	654	657	and
I-eligibility	657	658	/
I-eligibility	658	660	or
I-eligibility	661	673	chemotherapy
I-eligibility	673	674	/
I-eligibility	674	689	chemoprevention
I-eligibility	690	694	with
I-eligibility	695	698	CRF
I-eligibility	699	700	(
I-eligibility	700	705	Brief
I-eligibility	706	713	Fatigue
I-eligibility	714	723	Inventory
I-eligibility	724	725	>
I-eligibility	726	728	25
I-eligibility	728	729	)
O	729	730	.

O	731	734	The
O	735	742	primary
O	743	750	outcome
O	751	754	was
O	755	758	the
B-outcome-Measure	759	775	Multidimensional
I-outcome-Measure	776	783	Fatigue
I-outcome-Measure	784	793	Inventory
I-outcome-Measure	794	795	(
I-outcome-Measure	795	798	MFI
I-outcome-Measure	798	799	)
O	799	800	,
O	801	805	with
O	806	809	the
O	810	818	National
O	819	829	Institutes
O	830	832	of
O	833	839	Health
O	840	846	PROMIS
O	847	854	Fatigue
O	855	860	scale
O	861	870	secondary
O	870	871	.

O	872	876	Mean
O	877	885	baseline
O	886	889	MFI
O	890	896	scores
O	897	900	for
B-total-participants	901	903	57
O	904	913	evaluable
O	914	922	subjects
O	923	927	were
O	928	930	62
O	930	931	.
O	931	933	95
O	934	937	for
O	938	941	SMT
O	941	942	,
O	943	945	55
O	945	946	.
O	946	948	00
O	949	952	for
O	953	955	LT
O	955	956	,
O	957	960	and
O	961	963	60
O	963	964	.
O	964	966	41
O	967	970	for
O	971	974	WLC
O	974	975	.

O	976	979	SMT
O	980	988	resulted
O	989	991	in
O	992	993	a
O	994	998	mean
O	999	1000	(
O	1000	1008	standard
O	1009	1018	deviation
O	1018	1019	)
O	1020	1021	6
O	1021	1022	-
O	1022	1026	week
B-outcome	1027	1036	reduction
I-outcome	1037	1039	in
I-outcome	1040	1043	MFI
I-outcome	1044	1049	total
I-outcome	1050	1056	scores
O	1057	1059	of
B-iv-cont-mean	1060	1061	-
I-iv-cont-mean	1061	1063	16
I-iv-cont-mean	1063	1064	.
I-iv-cont-mean	1064	1066	50
O	1067	1068	(
B-iv-cont-sd	1068	1069	6
I-iv-cont-sd	1069	1070	.
I-iv-cont-sd	1070	1072	37
O	1072	1073	)
O	1074	1075	(
O	1075	1076	n
O	1077	1078	=
B-intervention-participants	1079	1081	20
O	1081	1082	)
O	1083	1089	versus
B-iv-cont-mean	1090	1091	-
I-iv-cont-mean	1091	1092	8
I-iv-cont-mean	1092	1093	.
I-iv-cont-mean	1093	1095	06
O	1096	1097	(
B-iv-cont-sd	1097	1098	6
I-iv-cont-sd	1098	1099	.
I-iv-cont-sd	1099	1101	50
O	1101	1102	)
O	1103	1106	for
O	1107	1109	LT
O	1110	1111	(
O	1111	1112	n
O	1113	1114	=
B-intervention-participants	1115	1117	20
O	1117	1118	)
O	1119	1122	and
O	1123	1125	an
O	1126	1134	increase
O	1135	1137	of
B-cv-cont-mean	1138	1139	5
I-cv-cont-mean	1139	1140	.
I-cv-cont-mean	1140	1142	88
O	1143	1144	(
B-cv-cont-sd	1144	1145	6
I-cv-cont-sd	1145	1146	.
I-cv-cont-sd	1146	1148	48
O	1148	1149	)
O	1150	1156	points
O	1157	1160	for
O	1161	1164	WLC
O	1165	1166	(
O	1166	1167	n
O	1168	1169	=
B-control-participants	1170	1172	17
O	1172	1173	)
O	1174	1175	(
O	1175	1184	treatment
O	1184	1185	-
O	1185	1187	by
O	1187	1188	-
O	1188	1192	time
O	1193	1194	P
O	1195	1196	<
O	1197	1198	.
O	1198	1202	0001
O	1202	1203	)
O	1203	1204	.

O	1205	1208	The
B-outcome	1209	1213	mean
I-outcome	1214	1222	baseline
I-outcome	1223	1229	PROMIS
I-outcome	1230	1237	Fatigue
I-outcome	1238	1244	scores
O	1245	1249	were
O	1250	1253	SMT
O	1253	1254	,
B-iv-cont-mean	1255	1257	22
I-iv-cont-mean	1257	1258	.
I-iv-cont-mean	1258	1260	25
O	1260	1261	;
O	1262	1264	LT
O	1264	1265	,
B-iv-cont-mean	1266	1268	22
I-iv-cont-mean	1268	1269	.
I-iv-cont-mean	1269	1271	05
O	1271	1272	;
O	1273	1276	and
O	1277	1280	WLC
O	1280	1281	,
B-cv-cont-mean	1282	1284	23
I-cv-cont-mean	1284	1285	.
I-cv-cont-mean	1285	1287	24
O	1287	1288	.

O	1289	1292	The
B-outcome	1293	1297	mean
I-outcome	1298	1299	(
I-outcome	1299	1307	standard
I-outcome	1308	1317	deviation
I-outcome	1317	1318	)
I-outcome	1319	1328	reduction
I-outcome	1329	1331	in
I-outcome	1332	1338	PROMIS
I-outcome	1339	1346	Fatigue
I-outcome	1347	1353	scores
O	1354	1357	was
B-iv-cont-mean	1358	1359	-
I-iv-cont-mean	1359	1360	5
I-iv-cont-mean	1360	1361	.
I-iv-cont-mean	1361	1363	49
O	1364	1365	(
B-iv-cont-sd	1365	1366	2
I-iv-cont-sd	1366	1367	.
I-iv-cont-sd	1367	1369	53
O	1369	1370	)
O	1371	1377	points
O	1378	1381	for
O	1382	1385	SMT
O	1386	1392	versus
B-iv-cont-mean	1393	1394	-
I-iv-cont-mean	1394	1395	3
I-iv-cont-mean	1395	1396	.
I-iv-cont-mean	1396	1398	24
O	1399	1400	(
B-iv-cont-sd	1400	1401	2
I-iv-cont-sd	1401	1402	.
I-iv-cont-sd	1402	1404	57
O	1404	1405	)
O	1406	1412	points
O	1413	1416	for
O	1417	1419	LT
O	1420	1423	and
B-cv-cont-mean	1424	1425	-
I-cv-cont-mean	1425	1426	0
I-cv-cont-mean	1426	1427	.
I-cv-cont-mean	1427	1429	06
O	1430	1431	(
B-cv-cont-sd	1431	1432	1
I-cv-cont-sd	1432	1433	.
I-cv-cont-sd	1433	1435	88
O	1435	1436	)
O	1437	1443	points
O	1444	1447	for
O	1448	1451	WLC
O	1452	1453	(
O	1453	1462	treatment
O	1462	1463	-
O	1463	1465	by
O	1465	1466	-
O	1466	1470	time
O	1471	1472	P
O	1473	1474	=
O	1475	1476	.
O	1476	1480	0008
O	1480	1481	)
O	1481	1482	.

O	1483	1489	Higher
O	1490	1501	credibility
O	1501	1502	,
O	1503	1513	expectancy
O	1513	1514	,
O	1515	1518	and
O	1519	1529	preference
O	1530	1533	for
O	1534	1537	SMT
O	1538	1542	than
O	1543	1546	for
O	1547	1549	LT
O	1550	1553	did
O	1554	1557	not
O	1558	1565	account
O	1566	1569	for
O	1570	1575	these
O	1576	1583	results
O	1583	1584	.

O	1585	1588	SMT
O	1589	1597	produced
O	1598	1608	clinically
O	1609	1620	significant
O	1621	1627	relief
O	1628	1630	of
O	1631	1634	CRF
O	1634	1635	.

O	1636	1640	This
O	1641	1648	finding
O	1649	1657	suggests
O	1658	1662	that
O	1663	1664	6
O	1665	1670	weeks
O	1671	1673	of
O	1674	1675	a
O	1676	1680	safe
O	1680	1681	,
O	1682	1688	widely
O	1689	1697	accepted
O	1698	1704	manual
O	1705	1717	intervention
O	1718	1724	causes
O	1725	1726	a
O	1727	1738	significant
O	1739	1748	reduction
O	1749	1751	in
O	1752	1759	fatigue
O	1759	1760	,
O	1761	1762	a
O	1763	1775	debilitating
O	1776	1783	sequela
O	1784	1787	for
O	1788	1794	cancer
O	1795	1804	survivors
O	1804	1805	.

O	1806	1812	Cancer
O	1813	1817	2018
O	1817	1818	;
O	1818	1821	124
O	1821	1822	:
O	1822	1825	546
O	1825	1826	-
O	1826	1828	54
O	1828	1829	.

O	1830	1831	Â©
O	1832	1836	2017
O	1837	1845	American
O	1846	1852	Cancer
O	1853	1860	Society
O	1860	1861	.
